Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Gabelli Funds LLC

Gabelli Funds LLC trimmed its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 19.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 356,600 shares of the company’s stock after selling 85,075 shares during the quarter. Gabelli Funds LLC’s holdings in Teva Pharmaceutical Industries were worth $11,129,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Allworth Financial LP grew its holdings in shares of Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares during the last quarter. Grove Bank & Trust grew its holdings in shares of Teva Pharmaceutical Industries by 300.0% in the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after acquiring an additional 750 shares during the last quarter. 1620 Investment Advisors Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 1,823.2% in the 4th quarter. 1620 Investment Advisors Inc. now owns 1,577 shares of the company’s stock worth $49,000 after acquiring an additional 1,495 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth $65,000. Finally, Rothschild Investment LLC grew its holdings in shares of Teva Pharmaceutical Industries by 97.0% in the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after acquiring an additional 1,348 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the business’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the completion of the sale, the executive vice president owned 172,184 shares of the company’s stock, valued at $6,131,472.24. The trade was a 47.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the completion of the sale, the executive vice president directly owned 55,755 shares of the company’s stock, valued at $1,973,727. This represents a 34.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 1,280,269 shares of company stock valued at $42,755,980. 0.54% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries News Summary

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Fitch upgraded Teva to investment grade, which may improve financing terms and highlights confidence in its turnaround execution. Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
• Positive Sentiment: Analyst commentary says Teva’s branded drug growth, biosimilars, and improving margins support a stronger long-term outlook. Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?
• Neutral Sentiment: Teva released new data showing many younger adults with mood disorders and tardive dyskinesia remain undiagnosed, supporting awareness of the company’s neuroscience market opportunity. Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
• Negative Sentiment: An executive sold a sizable block of shares, which can weigh on sentiment even if it reflects routine portfolio activity. Eliyahu Sharon Kalif Sells 153,251 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Bank of America lifted their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. The Goldman Sachs Group lifted their target price on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 2nd. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Finally, UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.78.

Teva Pharmaceutical Industries Trading Up 0.3%

NYSE:TEVA opened at $34.12 on Wednesday. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.99 and a 52 week high of $37.35. The stock’s 50 day moving average price is $31.65 and its 200 day moving average price is $30.70. The company has a market capitalization of $39.23 billion, a P/E ratio of 25.65, a P/E/G ratio of 3.29 and a beta of 0.86. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion during the quarter. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.